Source: Benzinga

Dianthus: Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February:Guggenheim SMID Cap Biotech Conference - Fireside ...Full story available on Benzinga.com

Read full article »
Annual Revenue
$100K-5.0M
Employees
25-100
Marino Garcia's photo - President & CEO of Dianthus

President & CEO

Marino Garcia

CEO Approval Rating

90/100

Read more